Cagrilintide vs Retatrutide

Overview

This comparison separates Cagrilintide and Retatrutide for reference—not product selection.

Cagrilintide: Long-acting amylin analogue studied on its own and combined with semaglutide in obesity trials.

Retatrutide: Investigational triple hormone receptor agonist studied in obesity and metabolic research.

Differences

• Cagrilintide belongs to amylin analogue research.
• Retatrutide belongs to GLP-1, GIP, and glucagon receptor research.

Mechanism

Cagrilintide: Amylin is released with insulin after eating and contributes to feeling full. Cagrilintide acts on the same receptors — the amylin and calcitonin receptors — bu…

Retatrutide: Retatrutide works across three hormone pathways involved in metabolism — the GLP-1, GIP and glucagon receptors. The plain-English version is that it uses three…

Pharmacology

Cagrilintide: Pharmacokinetic detail should be read from primary literature.

Retatrutide: Pharmacokinetic detail should be read from primary literature.

Research

Cagrilintide: Metabolic & GLP-1 research: Phase 3 trials demonstrate significant weight loss.

Retatrutide: Metabolic & GLP-1 research: Clinical trials show 17.5% weight loss at 24 weeks and 24.2% at 48 weeks.

Summary

Distinction

• AXIOM does not provide dosing, administration, or protocol guidance.
• Catalogue links appear only where AXIOM lists a research-use product.
• Reference-only compounds remain comparison terms without implying availability.

References

• pubmed.ncbi.nlm.nih.gov/37364590/
• pubmed.ncbi.nlm.nih.gov/40544432/
• pubmed.ncbi.nlm.nih.gov/40544433/
• pubmed.ncbi.nlm.nih.gov/37366315/
• pubmed.ncbi.nlm.nih.gov/40609566/
• pubmed.ncbi.nlm.nih.gov/41090431/
• pubmed.ncbi.nlm.nih.gov/39019866/
• pubmed.ncbi.nlm.nih.gov/37385280/

Questions